CPA
NRIX icon

Capital Performance Advisors’s Nurix Therapeutics NRIX Stock Holding History

Capital Performance Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18
Closed -$404 – 1806
2024
Q3 		$404 Buy
+18
New +$408 ﹤0.01% 2345

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Performance Advisors's NRIX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Nurix Therapeutics (NRIX) in Q4 2024, closing a stake of 18 shares — an estimated $404 sold.

Capital Performance Advisors first reported a position in NRIX in Q3 2024 and held it in 1 quarter. The position peaked at $404 in Q3 2024. 175 funds tracked by Wall St. Rank hold NRIX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Nurix Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 18 Nurix Therapeutics shares in Q4 2024, an estimated $404.
  • Capital Performance Advisors first reported a position in Nurix Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Nurix Therapeutics position peaked at $404 in Q3 2024.
  • 175 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.